News + Resources

Keep up with the latest

Featured

This Scientist Is Building Custom Gene-Editing Tools

This Scientist Is Building Custom Gene-Editing Tools

Epigenetic editors are a gentler form of gene editing

February 24, 2025

The Economist

Epigenetic editors are a gentler form of gene editing

February 24, 2025

Scribe Therapeutics Reports Preclinical Data Validating its CRISPR Genome Editing and Epigenome Modifying Technologies for Addressing Cardiometabolic Disease at American Heart Association (AHA) Scientific Sessions 2024

November 25, 2024

Scribe Therapeutics Reports Preclinical Data Validating its CRISPR Genome Editing and Epigenome Modifying Technologies for Addressing Cardiometabolic Disease at American Heart Association (AHA) Scientific Sessions 2024

November 25, 2024

CRISPR 2.0, the Next Generation

June 21, 2024

Aspen Ideas: Health

CRISPR 2.0, the Next Generation

June 21, 2024

The Age of CRISPR: Engineering the Future of Genetic Medicine

February 23, 2024

TEDxBerkeley

The Age of CRISPR: Engineering the Future of Genetic Medicine

February 23, 2024

All Stories

All
News
Press Releases
News

CRISPRMED25 Virtual Event Roundup

April 8, 2025

CRISPR Medicine News

Read Now
News

From Tools to Trials: Editing Therapy Companies Pivot to Development

March 20, 2025

Genetic Engineering & Biotechnology News

Read Now
News

Epigenetic editors are a gentler form of gene editing

February 24, 2025

The Economist

Read Now
News

CRISPR’s cardio catch-all drives a biotech’s broad potential

February 18, 2025

PharmaVoice

Read Now
News

Towards an AI-Driven CRISPR Future

February 11, 2025

SynBioBeta

Read Now
News

2025 predictions: Which trends are set to shape the biotech industry this year?

January 13, 2025

Labiotech

Read Now
Press release

Scribe Therapeutics Expands Collaboration With Biogen to Second Target

May 2, 2022

Read Now
Press release

Scribe Therapeutics to Participate in Upcoming Goldman Sachs The New Guard: Privates Leading the Disruption in Healthcare Investor Conference

April 1, 2022

Read Now
Press release

Scribe Therapeutics Appoints David Parrot as Chief Financial Officer and George Manning as Controller

March 9, 2022

Read Now
Press release

Scribe Therapeutics Raises $100M Series B Financing to Further Develop 'CRISPR by Design' Platform and Pipeline of Breakthrough Genetic Medicines

March 31, 2021

Read Now
Press release

Scribe Therapeutics Co-Founder Jennifer Doudna Receives 2020 Nobel Prize in Chemistry

October 9, 2020

Read Now
Press release

Scribe Therapeutics to Collaborate With Biogen to Develop CRISPR-based Genetic Medicines for Neurological Diseases Including ALS

October 6, 2020

Read Now

Publications and presentations